Document is current
Any future updates will be listed below
-
Authors
Duplan, Eric https://orcid.org/0000-0002-1348-1507
Bernardin, Aurore
Goiran, Thomas
Leroudier, Nathalie
Casimiro, Mathew
Pestell, Richard
Tanaka, Shinya https://orcid.org/0000-0001-6470-3301
Malleval, Celine
Honnorat, Jerome https://orcid.org/0000-0002-4721-5952
Idbaih, Ahmed
Martin, Lucie
Castel, Hélène https://orcid.org/0000-0002-8972-5555
Checler, Frédéric https://orcid.org/0000-0003-2098-1750
Alves da Costa, Cristine https://orcid.org/0000-0002-7777-005X
-
Funding
Funding for this research was provided by:
Ligue Contre le Cancer
LABEX Distaz
- License Information
-
More Information
Article History
Received: 29 July 2024
Revised: 17 February 2025
Accepted: 10 March 2025
First Online: 19 March 2025
Competing interests
: The authors declare no conflict of interest. RGP discloses ownership interests in Shenandoah Pharmaceuticals, EcoGenome, StromaGenesis, LightSeed, ioROC.
: This study was conducted in compliance with the principles of the Declaration of Helsinki. Informed consent was obtained from all the subjects. A written informed consent from all patients and a validation by a local ethical committee (obtained from the Centre de Recherche de l’Institut du Cerveau et de la Moelle Epinière, Groupe Hospitalier Pitié-Salpêtrière? Paris, France) were obtained for this study allowing molecular, genetic and translational research studies on cancer tissue samples. Animal experimental procedures were carried out in accordance with the Directive 2010/63/EU directive 2010/63/EU of the European parliament and of the council of 22 September 2010 after approval of the use of animals for experimental purposes by the local French Ethics.
